[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639419":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":46,"collaborators":50,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":72,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":10,"overallStatus":77,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Donors",null,"This group consists of healthy stool donors.",[13],"Other: Microbiome bank",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Microbiome bank","This is an observational study with no interventions.",[9],[20],{"name":21,"affiliation":5,"role":22},"Sean Spencer, MD, PhD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Roujheen Sabetan, MPH","CONTACT","650-498-8188","rsabetan@stanford.edu",[30],{"facility":5,"status":10,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Palo Alto","California","94305","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-122.14302,37.44188,{"lat":40,"lon":39},[43,44],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":45,"role":22,"phone":10,"phoneExt":10,"email":10},"Sean Spencer, MD, PHD",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Sean Spencer","Assistant Professor of Medicine and Medical Director of Microbiome Diagnostics and Therapeutics",[51,54,56],{"name":52,"class":53},"Kepner Microbiome Fund","UNKNOWN",{"name":55,"class":53},"Mischa Deeter Research Fund",{"name":57,"class":53},"GI Diseases Fund","100639419","stanford-university-microbiome-bank-100639419",false,"NCT07625059","Stanford University Microbiome Bank","SUMB","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Any person aged 18-80 years of age, inclusive at the time of signing the consent\n* In good general health as evidenced by medical history\n* Ability to travel to donation facility on a weekly basis\n* Residence within 5 miles of Stanford Campus\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation\n* Capable of providing signed informed consent.\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Enteric infections\n* Previous infection with Clostridium difficile\n* History of gastrointestinal surgery: Participants with gastrointestinal surgeries below the pylorus will be excluded from this protocol, including participants with a history of colectomy, segmental colonic resection, and small bowel resections.\n* Documented severe gastroparesis\n* Active intestinal obstruction\n* Dysphagia (oropharyngeal, esophageal, functional or neuromuscular)\n* History or current malignancy diagnosis\n* History of recurrent aspiration episodes\n* Any conditions associated with a high risk of bleeding, including but not limited to coagulopathy\u002Fbleeding disorder, severe liver disease, active or recent GI bleeding, or recent abdominal or other GI surgery\n* Active diagnosis of major depressive disorder\n* Active diagnosis of major anxiety disorder\n* Severe immunodeficiency, inherited or acquired (e.g., Human immunodeficiency virus, active chemotherapy or immunosuppressive medications \\[including steroids, biologic therapy, or bone marrow suppressive agents\\], or radiation therapy)\n* BMI of less than 18 or BMI greater than 30\n* Record of eating disorders\n* Active use of GLP-1 inhibitors\n* Diagnosis of Human immunodeficiency virus infection; Hepatitis A, B, C \\& E; Epstein Bar Virus; parasitic infections; Syphilis\n* Pregnancy \\& lactation\n* Active drug, or alcohol use disorder\n* Tobacco, marijuana and e-cigarette use\n* Any other significant medical condition that could confound or interfere with evaluation of safety or tolerability or prevent compliance with the study protocol at the discretion of the Investigator\n\nPrior\u002Fconcomitant therapy\n\n* Active antibiotic use\n* Active treatment with high levels of immunosuppressive therapies (active chemotherapy or immunosuppressive medications \\[including steroids, biologic therapy, or bone marrow suppressive agent\\], or radiation therapy)\n* Simultaneous participation in another interventional clinical trial\n\nOther exclusion criteria\n\n-Inability to comply with research requirements",true,"ALL","18 Years","80 Years",{"count":70,"type":71},50,"ESTIMATED","1 Year","OBSERVATIONAL","This protocol establishes a centralized stool donor bank and research platform to support microbiota transplantation therapy (MTT) for microbiota-mediated diseases. The study will characterize donor microbiome, metabolite, immune, and dietary profiles.",[76],"Healthy Adult Participants","NOT_YET_RECRUITING","2026-06-01",{"date":80,"type":81},"2026-06-04","ACTUAL",{"date":83,"type":71},"2026-08-01",{"date":85,"type":71},"2027-08-01",{"name":48,"class":6},1]